...
首页> 外文期刊>Pathology oncology research: POR >Overexpression of Pyruvate Kinase M2 in Tumor Tissues Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma
【24h】

Overexpression of Pyruvate Kinase M2 in Tumor Tissues Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma

机译:肿瘤组织中丙酮酸激酶M2的过度表达与肝细胞癌患者的预后不良有关

获取原文
获取原文并翻译 | 示例
           

摘要

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors, with a high degree of malignancy and a poor prognosis. The aim of this study was to investigate the relationship between expression of pyruvate kinase M2 (PKM2) and prognosis in patients with HCC. The expression levels of PKM2 and PKM1 in 86 cases of HCC were detected by immunohistochemistry. An H score was used to evaluate the expression of PKM, and all patients were further divided into PKM high-expression and PKM low-expression groups. The relationship between PKM2 expression and the clinicopathological parameters and prognosis of patients were subsequently analyzed. Our data suggested that the expression level of PKM2 was significantly higher in HCC tissues than in adjacent tissues and the negatively expression of PKM1 in HCC tissues. Kaplan-Meier analysis revealed that PKM2 expression was strongly associated with survival in HCC patients (P = 0.001). The patients in the PKM2 high-expression group had significantly shorter survival times than the patients in the PKM2 low-expression group (hazard ratio for death, 2.358; 95% confidence interval [1.156, 4.812]; P = 0.018). In conclusion, these data indicate that PKM2 expression in HCC tissue samples can be used as a prognostic factor for patients with HCC and that high PKM2 expression is correlated with a poor prognosis in HCC patients.
机译:肝细胞癌(HCC)是最常见的恶性肿瘤之一,具有很高的恶性肿瘤和预后差。本研究的目的是研究丙酮酸激酶M2(PKM2)表达与HCC患者预后的关系。免疫组织化学检测86例HCC病例中PKM2和PKM1的表达水平。 H评分用于评估PKM的表达,并且所有患者均进一步分为PKM高表达和PKM低表达基团。随后分析了PKM2表达与临床病理学参数和预后的关系。我们的数据表明,HCC组织中PKM2的表达水平显着高于相邻组织和HCC组织中PKM1的负面表达。 Kaplan-Meier分析表明,PKM2表达与HCC患者的存活强烈相关(P = 0.001)。 PKM2高表达组的患者比PKM2低表达组的患者(死亡危害比为2.358; 95%置信区间[1.156,4.812]; p = 0.018),患者的存活时间明显较短。总之,这些数据表明,HCC组织样品中的PKM2表达可以用作HCC患者的预后因素,并且高PKM2表达与HCC患者的预后差相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号